Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 128Melanoma 65Squamous Cell Carcinoma of Head and Neck 64Parkinson Disease 4, Autosomal Dominant Lewy Body 52Lung Neoplasms 51Triple Negative Breast Neoplasms 47Neoplasm Metastasis 45Breast Neoplasms 42Neoplasms 39Colorectal Neoplasms 34Carcinoma, Renal Cell 30Head and Neck Neoplasms 29Endometrial Neoplasms 28Ovarian Neoplasms 27Carcinoma, Transitional Cell 22Urinary Bladder Neoplasms 21Stomach Neoplasms 17Carcinoma 16Pancreatic Neoplasms 15Uterine Cervical Neoplasms 14Esophageal Neoplasms 13Brain Neoplasms 13Recurrence 12Sarcoma 11Hodgkin Disease 11Carcinoma, Squamous Cell 11Carcinoma, Hepatocellular 11Cholangiocarcinoma 10Skin Neoplasms 9Esophageal Squamous Cell Carcinoma 9

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumors × pembrolizumab × 90 days × Clear all
NCT07469774 2026-05-28

BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Biocity Biopharmaceutics Co., Ltd.

Phase 1/2 Recruiting
111 enrolled
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡